期刊文献+

原发性心内膜弹力纤维增生症预后相关因素分析

An analysis of the factors related to the prognosis of primary endocardial fibroelastosis
下载PDF
导出
摘要 目的:探讨原发性心内膜弹力纤维增生症(endocardial fibroelastosis,EFE)的临床特征及影响其预后的相关因素。方法:纳入2008年1月至2018年4月在重庆医科大学附属儿童医院心内科住院的EFE患儿150例(男52例,女98例),收集其起病年龄及体质量、临床症状、个人史、辅助检查等。其中出院后随访92例,根据随访时心功能及辅助检查结果分为缓解组(n=75)与恶化组(n=17),采用卡方检验、U检验进行统计学分析,采用logistic回归分析起病年龄及体质量、母孕期感染史、初诊心功能、心胸比、是否丙种球蛋治疗、随访时间与预后的关系。结果:①150例患儿起病中位年龄为163 d,中位体质量为7 kg,71.33%的患者2周内有前驱感染,72%以呼吸道症状起病,71.33%心功能Ⅰ级到Ⅱ级,28.67%心功能Ⅲ级,31.33%初诊心胸比≥0.70。心脏超声心内膜厚度中位数为2.5 mm,左室舒张期末内径(left ventricular end-diastolic diameter,LVDd)平均值为42.09 mm,左室短轴缩短率(left ventricular fraction shortening,LVFS)中位数为18%,左室射血分数(left ventricular ejection fraction,LVEF)平均值为38%。55.33%病毒抗体阳性。②92例出院后规律随访患儿中,缓解组与恶化组间起病年龄、随访时间、心胸比差异均有统计学意义(均P<0.05)。性别、母孕期感染史、初诊心功能分级、丙种球蛋白治疗在两组间差异均无统计学意义(均P>0.05)。采用二元logistic回归矫正性别、起病年龄、有无母孕期感染史、初诊心功能分级、是否丙种球蛋白治疗等混杂因素后,初诊心胸比小于0.7的患儿缓解概率明显升高(OR=6.89,95%CI=1.54~25.68),规律随访时间小于2年的患儿缓解概率明显降低(OR=0.11,95%CI=0.03~0.49)。结论:EFE多发于婴幼儿,大部分患儿有前驱感染史或母孕期有感染史。初诊时心胸比小于0.7及随访时间大于2年为该病缓解的保护因素。 Objective:To investigate the clinical features of primary endocardial fibroelastosis(EFE)and the factors affecting its prognosis. Methods:A total of 150 children with EFE(52 males and 98 females)who were hospitalized in the Department of Cardiology in Children’s Hospital of Chongqing Medical University from January 2008 to April 2018 were enrolled. The age,body weight,clinical symptoms,personal history,and auxiliary examinations of the children at disease onset were collected. Among these patients,92 were followed up after discharge from the hospital and were divided into remission group(n=75)and deterioration group(n=17)according to their cardiac function and auxiliary examination results at follow-up. The chi-square test and U test were used for statistical analysis.Logistic regression was used to analyze the association of age and body weight of the patients at disease onset,maternal infection history,cardiac function,and cardiothoracic ratio at initial diagnosis,status of gamma-globulin treatment,and duration of follow-up with prognosis. Results:The median age and median body weight of the 150 children at disease onset were 163 days and 7 kg,respectively;71.33% of the patients had a prodromal infection within two weeks,72% had respiratory symptoms as their earliest manifestations,71.33% had a cardiac function of grade Ⅰ-Ⅱ,28.67% had a cardiac function of grade Ⅲ,and 31.33% had a cardiothoracic ratio of≥0.70 at initial diagnosis. The median endocardial thickness,mean LVDd,median LVFS,and mean LVEF were 2.5 mm,42.09 mm,18%,and 38%,respectively. Fifty-five point three-three percent of the patients had positive viral antibody test results. Among the 92 children being regularly followed up,there were significant differences in age at disease onset,duration of follow-up,and cardiothoracic ratio between the remission group and the deterioration group(P<0.05),but there were no significant differences in sex,maternal infection history,cardiac functional grading at initial diagnosis,or status of gamma-globulin treatment between the two groups(P>0.05). After correction of the confounding factors such as sex,age at disease onset,maternal infection history,cardiac functional grading at initial diagnosis,and status of gamma-globulin treatment using binary logistic regression,the percentage of remitted children with a cardiothoracic ratio of <0.7 at initial diagnosis increased significantly(OR=6.89,95%CI=1.54 to 25.68),and the percentage of remitted children with a regular follow-up of <2 years decreased significantly(OR=0.11,95%CI=0.03 to 0.49). Conclusion:EFE is prevalent in infants and young children,most of whom have a history of prodromal infection or maternal infection. An initial cardiothoracic ratio of <0.7 and a follow-up of >2 years are protective factors for remission of the disease.
作者 汪谚秋 易岂建 Wang Yanqiu;Yi Qijian(Department of Cardiovascular Medicine,Children’s Hospital of Chongqing Medical University,Ministry of Education Key Laboratory of Child Development and Disorders,China International Science and Technology Cooperation Base of Child Development and Critical Disorders,Chongqing Key Laboratory of Pediatrics)
出处 《重庆医科大学学报》 CAS CSCD 北大核心 2020年第4期468-471,共4页 Journal of Chongqing Medical University
关键词 心内膜弹力纤维增生症 原发性 临床特征 预后 endocardial fibroelastosis primary clinical feature prognosis
  • 相关文献

参考文献3

二级参考文献25

  • 1徐健,朴金花,韩燕燕.心内膜弹力纤维增生症诊断治疗12年回顾[J].中华临床医师杂志(电子版),2011,5(22):6842-6843. 被引量:4
  • 2王惠玲,孙国贤.33例小儿心内膜弹力纤维增生症的诊断及治疗[J].中华医学杂志,1993,73(7):396-399. 被引量:6
  • 3陈瑾,胡大一,张麟,刘秀兰,吴雅峰,李静.卡维地洛对心脏β_1、β_2和α_1受体自身抗体及心功能的影响[J].中华心血管病杂志,2005,33(6):498-501. 被引量:69
  • 4杨英珍.病毒性心肌病[M].上海:上海科学技术出版社,2001.110.
  • 5倪时和,梁翊常,李佩娟,等.心内膜弹性纤维组织增生症病因探讨(102例临床病理分析).中华儿科杂志,1987,25:330-332.
  • 6Ni J,Bowles Ne,Kim YH,et al.Viral infection of the myocar-dium in endocardial fibroelastosis.Circulation,1997,95:133-139.
  • 7Rabinovitch N,Gelfand EW,Leung DY.The role of immuno-globulin therapy in allergic diseases.Allergy,1999,54:662-668.
  • 8Maisch B,Hufnagel G,Klsch S,et al,Treatment of inflamma-tory dilated cardiomyopathy and(peri)myocarditis with immuno-suppression and i.v.immunoglobulins.Herz,2004,29:624-636.
  • 9Andersson DC,Marks AR.Fixing ryanodine receptor Ca2+ leak-anovel therapeutic strategy for contractile failure in heart and skeletal muscle[J].Drug Discov Today Dis Mech,2010,7: 151-157.
  • 10Arya SO,Karpawich PP,Gupta P,et al.Primary endocardial fibroelastosis presenting in a young child as incessant ventricular tachycardia and dilated cardiomyopathy[J].Tex Heart Inst J,2012,39(5): 714-718.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部